Key facts
- KinoPharma’s last known valuation is $42.7M (Jul 2023).
- It has raised $29.9M; the latest was Later Stage VC in Feb 2025.
- Notable investors include Mitsubishi UFJ Capital, Resona Capital, Kyoto University Innovation Capital, Kyoshin Social Capital, Awagin Capital — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for KinoPharma
- ·The full record, as it builds
Funding rounds
No funding rounds for KinoPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KinoPharma
Developer of molecule drugs designed to provide antiviral medication to women for papillomavirus (HPV) infection. The company's research responds to the discovery and clinical development of next-generation antifungal remedies using an approach different from conventional antibacterial medicine strategies, enabling women to treat cervical cancer before it develops.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2005
- Website
- kinopharma.com/
- Ownership
- Privately Held (backing)
KinoPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KinoPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KinoPharma in its N-PORT filings yet. We sweep new filings monthly.